Skip to main content
Premium Trial:

Request an Annual Quote

Caliper, Monogram Removed from Nasdaq Biotech Index

NEW YORK (GenomeWeb News) – Caliper Life Sciences and Monogram Biosciences are among the firms that are being removed from the Nasdaq Biotechnology Index as of the open of the market on May 18.

The Nasdaq Biotech Index performs a semi-annual re-ranking of biotech firms that it considers for either adding or dropping from the Index. In this most recent re-ranking, it added four drug firms and dropped 16 firms.

The other research products firm that was dropped from the Index was Harvard Bioscience.

Securities in the Index must meet certain eligibility criteria, such as minimum requirements for market value, average daily share volume, and seasoning as a public company. The next re-ranking will occur in November.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.